Annual report
7733.TEDINET S100OBAY
Period2021-04-01 → 2022-03-31
Filed2022-06-21
StandardIFRS
ConsolidatedYes
Data checks19 of 19 passed
Key figures · 170
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥868.9bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥730.5bn | 2020-04-01 → 2021-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥755.2bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥793.9bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥789.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥786.5bn | 2017-04-01 → 2018-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥153.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥82.0bn | 2020-04-01 → 2021-03-31 | Cons. | Operating profit loss IFRS |
| Ordinary income | ¥61.3bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥149.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥76.8bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥86.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥76.7bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥115.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥12.9bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥51.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥8.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥46.2bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥57.1bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥116.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥13.0bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.36T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.18T | at 2021-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.02T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥932.0bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥967.6bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥978.7bn | at 2018-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥846.6bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥788.0bn | at 2021-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥395.5bn | at 2021-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥372.0bn | at 2020-03-31d | Cons. | Equity IFRS |
| Net assets / equity | ¥443.0bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Equity (owners) | ¥510.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥394.3bn | at 2021-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥370.7bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥441.2bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥442.8bn | at 2018-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥302.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.5bn | at 2021-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥162.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥114.6bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥191.2bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥191.2bn | at 2018-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥169.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥124.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥133.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥66.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥84.8bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥95.1bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥71.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥118.9bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥62.4bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥60.3bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥43.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥53.3bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥40.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥40.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥19.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥82.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥51.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥90.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥10.05 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.37 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥5.97 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥33.76 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.71 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥90.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥10.04 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥39.36 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥5.96 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥33.74 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥41.69 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥400.75 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥306.72 | at 2021-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥288.39 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥323.06 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥324.37 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥324.25 | at 2018-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 33.3% | at 2021-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 36.5% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 47.3% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 45.6% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.2% | at 2018-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 25.6% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 3.4% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.7% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 1.8% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.1% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.6% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 31,557 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 31,653 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 35,174 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 35,124 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 35,933 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥378.6bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥344.1bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥375.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥376.8bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥377.5bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥45.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥28.6bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥57.2bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥49.0bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥13.3bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥44.0bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥14.1bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥95.0bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥868m | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥84.8bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥8.5bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥9.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥30.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥15.2bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥900.9bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥826.6bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥771.0bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥745.8bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥786.5bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥543.7bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥476.8bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥357.2bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥349.8bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥376.2bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥471.4bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥455.4bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥46m | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥40.1bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥66.13 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥6.64 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.51 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.13 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥11.1 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥66.1 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥6.64 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.51 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.12 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥11.09 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥14 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥280.3 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥271.69 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥292.24 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥344.8 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥333.07 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 39.6% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.8% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 24.0% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,299,294,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,370,915,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,370,915,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 342,713,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 342,691,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,478 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,775 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 7,146 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 7,024 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 6,926 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 524 pure |
| Otherother segments | capex | 2021-04-01 → 2022-03-31 | ¥997m |
| Otherother segments | segment assets | at 2022-03-31 | ¥20.7bn |
| Otherother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥2.0bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥8.1bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥318.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥55.6bn |
| Endoscopicreportable segment | employees | at 2022-03-31 | 13646 pure |
| Endoscopic Solutionsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥40.4bn |
| Endoscopic Solutionsreportable segment | segment assets | at 2022-03-31 | ¥493.6bn |
| Endoscopic Solutionsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥133.2bn |
| Scientific Solutionsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Scientific Solutionsreportable segment | employees | at 2022-03-31 | 3709 pure |
| Scientific Solutionsreportable segment | segment assets | at 2022-03-31 | ¥112.3bn |
| Scientific Solutionsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥17.5bn |
| Therapeuticreportable segment | employees | at 2022-03-31 | 8252 pure |
| Therapeutic Solutionsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥16.3bn |
| Therapeutic Solutionsreportable segment | segment assets | at 2022-03-31 | ¥412.9bn |
| Therapeutic Solutionsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥60.8bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥67.4bn |
| —segment total | segment assets | at 2022-03-31 | ¥1.04T |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥209.5bn |
| Otherother segments | capex | 2020-04-01 → 2021-03-31 | ¥928m |
| Otherother segments | segment assets | at 2021-03-31 | ¥20.5bn |
| Otherother segments | segment profit | 2020-04-01 → 2021-03-31 | −¥682m |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥13.7bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥271.1bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥51.6bn |
| Endoscopic Solutionsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥50.9bn |
| Endoscopic Solutionsreportable segment | segment assets | at 2021-03-31 | ¥451.3bn |
| Endoscopic Solutionsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥98.8bn |
| Scientific Solutionsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥9.1bn |
| Scientific Solutionsreportable segment | segment assets | at 2021-03-31 | ¥97.1bn |
| Scientific Solutionsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥4.9bn |
| Therapeutic Solutionsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥24.4bn |
| Therapeutic Solutionsreportable segment | segment assets | at 2021-03-31 | ¥343.5bn |
| Therapeutic Solutionsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥30.6bn |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥85.3bn |
| —segment total | segment assets | at 2021-03-31 | ¥912.3bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥133.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 17 pure |
| Endoscopicreportable segment | employees | at 2022-03-31 | 442 pure |
| Scientific Solutionsreportable segment | employees | at 2022-03-31 | 736 pure |
| Therapeuticreportable segment | employees | at 2022-03-31 | 216 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,914
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02272-000TherapeuticReportableSegmentMember | 216 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02272-000ScientificSolutionsReportableSegmentMember | 736 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 17 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 2067 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 3478 | |
| Research and development expenses research and development activities | CurrentYearDuration | 85300000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02272-000EndoscopicSolutionsReportableSegmentMember | 39300000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02272-000TherapeuticSolutionsReportableSegmentMember | 20700000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02272-000ScientificSolutionsReportableSegmentMember | 10100000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_OtherReportableSegmentsMember | 15200000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 75500000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02272-000EndoscopicSolutionsReportableSegmentMember | 40400000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02272-000TherapeuticSolutionsReportableSegmentMember | 16300000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02272-000ScientificSolutionsReportableSegmentMember | 9600000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_OtherReportableSegmentsMember | 1000000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 1299294333 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 1285892000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 1299294333 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 1285892000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 71 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 54 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 374 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 852 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 92 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 38674 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 40117 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 4955489 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 214965 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 308549 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 6697558 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 691 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 814009 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 12991261 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 168233 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.3814 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0165 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.0238 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.5156 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0000 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.0627 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 243809100 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.1915 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 87088376 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0684 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 78118300 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0614 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 19 of 19 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |